Global Immunoassay Market Size and Forecast:
Intense developments in the field of genomics and proteomics has expanded the database of biomarkers used by industry players to develop new assays that cascade the onset of a disease or disorder. The global immunoassays market is set to register impressive growth, expanding at a healthy 6.0% CAGR during the forecast period (2020-2026).
Key players are investing in the development of novel immunoassays in the infectious diseases domain, with increasing database on genetics and biomarkers of various infectious pathogens. Immunoassay analyzers such as enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA) and immunofluorescence assay (IFA) are preferred choices for the diagnosis of infectious diseases.
Immunoassay Manufacturers: Strategies
Rising demand for early detection and diagnosis of autoimmune disorders has also augmented development of new immunoassay systems by leading players in the in-vitro diagnostics industry. For instance, in December 2017, Innova diagnostics launched the next-generation EIA & IFA Processor QUANTA-Lyser 3000 for the diagnosis of autoimmune disorders in clinical laboratories. In addition, the current COVID-19 pandemic has also prompted key players to invest heavily in the development of immunoassays to eradicate the SARS-CoV-2 virus. For instance, Bio-Rad Corporation announced the launch of a blood-immunoassay kit for the identification of antibodies to the novel coronavirus in April 2020.
Immunoassay Market Segmentation
Immunoassay Market Share by Technology
The chemiluminescence immunoassays (CLIA) segment was valued at US$ 7.8 Bn in 2017, and is expected to reach US$ 14 Bn by 2026, expanding at a strong CAGR of 6.6%. This is followed by the enzyme-linked immunosorbent assays (ELISA) segment, which is projected to reach a value of US$ 8.9 Bn and growing at a rate of 5.8% in the same period.
Growth of the CLIA segment is attributed to burgeoning investments by key market players in emerging markets. This is especially the case in the Asia-Pacific region, where the number of infectious diseases is on the rise. Moreover, affordability and easy availability and compatibility with various in-house IVD reagents is projected to drive the ELISA market forward during the forecast period.
To know more about the immunoassay market, ask an analyst here
Immunoassay Market Share by Product
The consumables segment is poised to expand at the highest CAGR of 6.2% between 2020 and 2026, attributed to widespread adoption of immunoassay tests for the diagnosis of infectious diseases and endocrinal disorders. The segment was valued at US$ 13 Bn in 2017 and is expected to increase to US$ 23 Bn by 2026. The analyzers segment is poised to capture around 1/5th of the global immunoassays market share. Availability of multiplexed and integrated analyzers with high throughput and reduced waiting time is anticipated to drive the growth of the analyzers segment in the forecast period.
Immunoassay Market Share by Application
Endocrine disorders have registered a significant uptick in recent years. As a consequence, healthcare providers have started using immunoassay machines to treat the same. The endocrinology segment is poised to expand the fastest, at a healthy CAGR of 6.5% by 2026, capturing nearly one-fifth of the total market share. The infectious diseases segment shall grow at an equivalent CAGR, capturing nearly 30% of the global immunoassays market.
Endocrinology tests have a wide range of applications, which include but are not limited to immunoassay analyzer testing, anti-TSH receptors testing, fertility testing and women’s health testing. Such widespread applications are important growth catalysts for the segment. Similarly, rising number of infectious diseases is augmenting the growth of the infectious diseases segment. The ongoing COVID-19 pandemic has especially seen a burgeoning trend of immunoassay types to ascertain the prognosis of the disease as well as finding potential antibodies to eradicate the deadly virus.
Immunoassay Market Share by Region
The North American immunoassay market is poised to dominate, accounting for nearly 40% of the total share and registering a CAGR of 6.0% across the forecast period. A growing trend of mergers & acquisitions is observed among in-vitro diagnostic and life sciences players in North America. This is anticipated to largely propel the region’s growth in the future. These players are looking to strengthen their product portfolio by venturing into various medical specialty domains.
Asia-Pacific promises to emerge as the fastest growing region, recording an impressive CAGR of 7.0% throughout the forecast period. The region is anticipated to capture nearly a quarter of the global immunoassay market. This growth is attributed to high prevalence and incidence rate of chronic and infectious diseases, which has increased per capita healthcare expenditure. Additionally, intensifying competition among diagnostic laboratories and hospitals and subsequent differentiation of products is expected to leverage demand for high-quality immunoassay analyzers, reagents and kits in the Asia-Pacific market.
To get the latest COVID-19 impact insights on immunoassays market, request for a report sample here
Immunoassay Manufacturer Insights: Development of Advanced Immunoassay to Drive Market Players’ Growth
The global immunoassay market is highly consolidated. The top four market players constitute more than half of the total market share. These players are: F. Hoffmann La-Roche Ltd. (Roche Holdings AG), Abbott Laboratories, Siemens Healthineers and Beckman Coulter, Inc. (Danaher). These players have consolidated their operations by virtue of important collaborations to burgeon production of immunoassay kits.
La-Roche, for instance, offers products such as the COBAS C 702 & E 602 Module, the COBAS 4000 & 6000 Analyzer series and Elecsys Assays. Likewise, Abbott Laboratories offers biotin-free assays to prevent interference in testing and the resulting inaccuracies. Other prominent immunoassay players include DiaSorin S.p.A., Sysmex Corporation, bioMerieux SA, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company and Merck KGaA.
COVID-19’s Impact on Global Immunoassay Market:
The COVID-19 pandemic is anticipated to heighten growth prospects for the global immunoassay market, as companies are increasingly directing research and development towards developing robust testing systems to ascertain potential antibodies which may assist in eradicating the novel coronavirus. Laboratories and diagnostic companies across the world are racing to produce antibody tests. Serology-based testing is in particularly high demand. This is attributed to its ability to quantify the number of COVID-19 cases, including those who may be asymptomatic or have recovered. ELISA-based testing is equally gaining traction in this regard. At present, Epitope Diagnostics, Inc. is offering the EDI Novel Coronavirus COVID-19 ELISA kits for qualitative detection of the COVID-19 IgG and IgM in human serum.
More recently, Bio-Rad Corporation announced the launch of a blood-based immunoassay kit for the identification of antibodies to the SARS-CoV-2. The company has established preliminary performance of the assay and has been clinically evaluated in multiple hospitals to further confirm its performance. Also, Thermo Fisher Scientific is offering its Singleplex kit for SARS-CoV-2 pathogen detection which is based on the RT-PCR technique. Furthermore, the company predicted that COVID-19 testing could create a tailwind of US$ 750 million in the second quarter of 2020. However, the benefits are more likely to be offset by disruptions, leading to an overall decline in the company’s sales by around 15%.
“Introduction of integrated systems coupled with development of ultrasensitive analyzer systems are anticipated to leverage prospects for the global immunoassay market. In addition, the novel coronavirus outbreak has provided a pathway for market expansion. North America and the Asia-Pacific regions are anticipated to provide credible growth opportunities, attributed to increased forays by leading market players to penetrate into respective markets.”
Global Immunoassay Market Report Scope
The recent study undertaken by Fact.MR on the global immunoassay market incorporates a six-year forecast period ranging from 2020 to 2026. The report elaborates on the key drivers, opportunities and restraints existing for the global immunoassay market in the future. The report incorporates a detailed assessment of key segments in terms of their revenue, market share and growth rate. Market segmentation has been done on the basis of technology, product, application and end-user.
A section on regional analysis has been embedded in the report. The regional analysis has been carried out for the following geographies: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa (MEA). Each region incorporates the segmental analysis mentioned above. In addition, a competitive landscape detailing key players’ market and revenue shares, strategies for expansion, key collaborations and SWOT analysis, has been incorporated within the scope of this report. Overall, the report presents an optimistic scenario of the global immunoassay market.
Global Immunoassays Market- Scope of the Report
The recent study by Fact.MR on the global immunoassays market offers a 6-year forecast between 2020 and 2026. The study analyzes crucial trends that are currently determining the growth of the global immunoassays market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the development of immunoassays. The study also provides dynamics responsible for influencing the future status of the market over the forecast period.
A detailed assessment of the global immunoassays market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global immunoassays market along with their product portfolio enhances the reliability of this comprehensive research study.
Global Immunoassays Market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in global immunoassays markets across the globe.
A comprehensive estimate of the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global immunoassays market during the forecast period. Price point comparison by region with global average price is also considered in the study.
Global Immunoassays: Market Segmentation
Fact.MR has studied the global immunoassays market with detailed segmentation on the basis of technology, product, application, end-user and region.
Chemiluminescence Immunoassay (CLIA)
Hospitals & Diagnostic Laboratories
Enzyme-linked Immunosorbent Assay (ELISA)
Enzyme Linked Fluorescence Assay (ELFA)
Others (Pharmaceutical & Biotech Companies, Academic & Research Institutes, Forensic Labs, etc.)
Middle East & Africa (MEA)
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Global Immunoassays Market: Analysis on Market Size Evaluation
The global immunoassays market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for global immunoassays is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent global immunoassays market segments, along with market attractiveness evaluation, has been incorporated in the report.
Global Immunoassays Market: Inspected Assessment on Regional Segments
Key sections have been elaborated in the global immunoassays report, which have helped deliver projection on the regional markets. These chapters include the regional macros (economic, and business environment outlook), which are expected to have a momentous influence on the growth of the global immunoassays market during the forecast period.
Country-specific valuation on demand for global immunoassays has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value for emerging countries has also been included in the report.
Global Immunoassays Market: In-Depth Analysis on Competitive Landscape
The report sheds light on the leading providers of global immunoassays along with their detailed profiles. Essential and up-to-date data information related to market performers, who are principally engaged in the production of global immunoassays, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis of each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global immunoassays market. Prominent manufacturers with established market presence in global immunoassays market are F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories, Siemens Healthineers (Siemens AG), DiaSorin S.p.A., Sysmex Corporation, bioMerieux SA, Ortho Clinical Diagnostics, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company and Merck KGaA.
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2 Assumptions and Research Methodology
3 Executive Summary: Global Immunoassay Market
4 Market Overview
4.2. Key Industry Developments
5 Market Dynamics
5.4. Key Trends
5.5. Global Immunoassay Market Size (US$ Mn) Forecast, 2020–2026
5.6. Global Immunoassay Market Outlook
5.7. Industry Mergers & Acquisitions
5.8. Automate Immunoassay Analyzer Volume
5.9. Distributor Analysis
5.10. Regulatory Assessments, by Key Country/Region
5.11. Winning Imperatives
6 Global Immunoassay Market Analysis and Forecast, by Technology
6.1. Key Findings
6.3. Market Size (US$ Mn) Forecast, by Technology, 2020–2026
6.3.1. Chemiluminescence Immunoassay (CLIA)
6.3.2. Enzyme-linked Immunosorbent Assay (ELISA)
6.3.3. Enzyme-linked Fluorescent Assay (ELFA)
6.3.4. Radioimmunoassay (RIA)
6.3.5. Others ( Microarray, Immunofluorescence Assay Biochip Assay, Counting Immunoassay)
6.4. Market Attractiveness Analysis, by Technology
7 Global Immunoassay Market Analysis and Forecast, by Product
7.1. Key Findings
7.3. Market Size (US$ Mn) Forecast, by Product, 2020–2026
7.4. Market Attractiveness Analysis, by Product
8 Global Immunoassay Market Analysis and Forecast, by Application
8.1. Key Findings
8.3. Market Size (US$ Mn) Forecast, by Application, 2020–2026
8.3.1. Infectious Disease
8.3.6. Others (Autoimmune Disorders, Allergy, Therapeutic Drug Monitoring, Liver Diseases, Acid Base Tests, GI Stool Testing, etc.)
8.4. Market Attractiveness Analysis, by Application
9 Global Immunoassay Market Analysis and Forecasts, by End-user
9.1. Key Findings
9.2. Market Size (US$ Mn) Forecast, by End-user, 2020–2026
9.2.1. Hospitals and Diagnostics Laboratories
9.2.2. Blood Banks
9.2.3. Others (Academic & Research Institutes, Pharmaceutical & Biotech Companies)
9.3. Market Attractiveness Analysis, by End-user
10 Global Immunoassay Market Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Global Market Scenario
10.3. Market Value (US$ Mn) Forecast, by Region, 2020–2026
10.3.1. North America
10.3.3. Asia Pacific
10.3.4. Latin America
10.3.5. Middle East & Africa
10.4. Market Attractiveness Analysis, by Region
10.5. Key Trends, by Region
11 North America Immunoassay Market Analysis and Forecast
11.1. Market Overview
11.2. Market Size (US$ Mn) Forecast, by Country, 2020–2026
11.3. Market Size (US$ Mn) Forecast, by Technology, 2020–2026
11.3.1. Chemiluminescence Immunoassay (CLIA)
11.3.2. Enzyme-linked Immunosorbent Assay (ELISA)
11.3.3. Enzyme Linked Fluorescent Assay (ELFA)
11.3.4. Radioimmunoassay (RIA)
11.4. Market Size (US$ Mn) Forecast, by Product, 2020–2026
11.5. Market Size (US$ Mn) Forecast, by Application, 2020–2026
11.5.1. Infectious Disease
11.6. Market Size (US$ Mn) Forecast, by End-user, 2020–2026
11.6.1. Hospitals and Diagnostics Laboratories
11.6.2. Blood Banks
11.7. Market Attractiveness Analysis
11.7.1. By Country
11.7.2. By Technology
11.7.3. By Product
11.7.4. By Application
11.7.5. By End-user
12 Europe Immunoassay market Analysis and Forecast
12.1. Market Overview
12.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2026
12.2.6. Rest of Europe
12.3. Market Size (US$ Mn) Forecast, by Technology, 2020–2026
12.3.1. Chemiluminescence Immunoassay (CLIA)
12.3.2. Enzyme-linked Immunosorbent Assay (ELISA)
12.3.3. Enzyme Linked Fluorescent Assay (ELFA)
12.3.4. Radioimmunoassay (RIA)
12.4. Market Size (US$ Mn) Forecast, by Product, 2020–2026
12.5. Market Size (US$ Mn) Forecast, by Application, 2020–2026
12.5.1. Infectious Disease
12.6. Market Size (US$ Mn) Forecast, by End-user, 2020–2026
12.6.1. Hospitals and Diagnostics Laboratories
12.6.2. Blood Banks
12.7. Market Attractiveness Analysis
12.7.1. By Country
12.7.2. By Technology
12.7.3. By Product
12.7.4. By Application
12.7.5. By End-user
13 Asia Pacific Immunoassay Market Analysis and Forecast
13.1. Market Overview
13.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2026
13.2.4. Australia & New Zealand
13.2.5. Rest of Asia Pacific
13.3. Market Size (US$ Mn) Forecast, by Technology, 2020–2026
13.3.1. Chemiluminescence Immunoassay (CLIA)
13.3.2. Enzyme-linked Immunosorbent Assay (ELISA)
13.3.3. Enzyme Linked Fluorescent Assay (ELFA)
13.3.4. Radioimmunoassay (RIA)
13.4. Market Size (US$ Mn) Forecast, by Product, 2020–2026
13.5. Market Size (US$ Mn) Forecast, by Application, 2020–2026
13.5.1. Infectious Disease
13.6. Market size (US$ Mn) Forecast, by End-user, 2020–2026
13.6.1. Hospitals and Diagnostics Laboratories
13.6.2. Blood Banks
13.7. Market Attractiveness Analysis
13.7.1. By Country
13.7.2. By Technology
13.7.3. By Product
13.7.4. By Application
13.7.5. By End-user
14 Latin America Immunoassay Market Analysis and Forecast
14.1. Market Overview
14.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2026
14.2.3. Rest of Latin America
14.3. Market Size (US$ Mn) Forecast, by Technology, 2020–2026
14.3.1. Chemiluminescence Immunoassay (CLIA)
14.3.2. Enzyme-linked Immunosorbent Assay (ELISA)
14.3.3. Enzyme Linked Fluorescent Assay (ELFA)
14.3.4. Radioimmunoassay (RIA)
14.4. Market Size (US$ Mn) Forecast, by Product, 2020–2026
14.5. Market Size (US$ Mn) Forecast, by Application, 2020–2026
14.5.1. Infectious Disease
14.6. Market Size (US$ Mn) Forecast, by End-user, 2020–2026
14.6.1. Hospitals and Diagnostics Laboratories
14.6.2. Blood Banks
14.7. Market Attractiveness Analysis
14.7.1. By Country
14.7.2. By Technology
14.7.3. By Product
14.7.4. By Application
14.7.5. By End-user
15 Middle East and Africa Immunoassay Market Analysis and Forecast
15.1. Market Overview
15.2. Market size (US$ Mn) Forecast, by Country/Sub-region, 2020–2026
15.2.1. GCC Countries
15.2.2. South Africa
15.2.3. Rest of Middle East and Africa
15.3. Market Size (US$ Mn) Forecast, by Technology, 2020–2026
15.3.1. Chemiluminescence Immunoassay (CLIA)
15.3.2. Enzyme-linked Immunosorbent Assay (ELISA)
15.3.3. Enzyme Linked Fluorescent Assay (ELFA)
15.3.4. Radioimmunoassay (RIA)
15.4. Market Size (US$ Mn) Forecast, by Product, 2020–2026
15.5. Market Size (US$ Mn) Forecast, by Application, 2020–2026
15.5.1. Infectious Disease
15.6. Market Size (US$ Mn) Forecast, by End-user, 2020–2026
15.6.1. Hospitals and Diagnostics Laboratories
15.6.2. Blood Banks
15.7. Market Attractiveness Analysis
15.7.1. By Country
15.7.2. By Technology
15.7.3. By Product
15.7.4. By Application
15.7.5. By End-user
16 Competition Landscape
16.1. Global Immunoassay Market Share, by Company, 2018
16.2. Market Player – Competition Matrix (By Tier and Size of Companies)
16.3. Company Profiles
16.3.1. F. Hoffmann-La Roche Ltd.
220.127.116.11. Company Overview (HQ, Business Segments, Employee Strength)
18.104.22.168. Product Portfolio
22.214.171.124. SWOT Analysis
126.96.36.199. Financial Overview
188.8.131.52. Strategic Overview
16.3.2. Danaher Corporation.
184.108.40.206. Company Overview (HQ, Business Segments, Employee Strength)
220.127.116.11. Product Portfolio
18.104.22.168. SWOT Analysis
22.214.171.124. Financial Overview
126.96.36.199. Strategic Overview
16.3.3. Abbott Laboratories.
188.8.131.52. Company Overview (HQ, Business Segments, Employee Strength)
184.108.40.206. Product Portfolio
220.127.116.11. SWOT Analysis
18.104.22.168. Financial Overview
22.214.171.124. Strategic Overview
16.3.4. Siemens Healthineers (Siemens AG)
126.96.36.199. Company Overview (HQ, Business Segments, Employee Strength)
188.8.131.52. Product Portfolio
184.108.40.206. SWOT Analysis
220.127.116.11. Financial Overview
18.104.22.168. Strategic Overview
16.3.5. DiaSorin S.p.A.
22.214.171.124. Company Overview (HQ, Business Segments, Employee Strength)
126.96.36.199. Product Portfolio
188.8.131.52. SWOT Analysis
184.108.40.206. Financial Overview
220.127.116.11. Strategic Overview
16.3.6. Sysmex Corporation.
18.104.22.168. Company Overview (HQ, Business Segments, Employee Strength)
22.214.171.124. Product Portfolio
126.96.36.199. SWOT Analysis
188.8.131.52. Financial Overview
184.108.40.206. Strategic Overview
16.3.7. bioMérieux SA
220.127.116.11. Company Overview (HQ, Business Segments, Employee Strength)
18.104.22.168. Product Portfolio
22.214.171.124. SWOT Analysis
126.96.36.199. Financial Overview
188.8.131.52. Strategic Overview
16.3.8. Ortho Clinical Diagnostics (a part of Carlyle Group).
184.108.40.206. Company Overview (HQ, Business Segments, Employee Strength)
220.127.116.11. Product Portfolio
18.104.22.168. SWOT Analysis
22.214.171.124. Financial Overview
126.96.36.199. Strategic Overview
16.3.9. Thermo Fisher Scientific, Inc.
188.8.131.52. Company Overview (HQ, Business Segments, Employee Strength)
184.108.40.206. Product Portfolio
220.127.116.11. SWOT Analysis
18.104.22.168. Financial Overview
22.214.171.124. Strategic Overview
16.3.10. Becton, Dickinson and Company.
126.96.36.199. Company Overview (HQ, Business Segments, Employee Strength)
188.8.131.52. Product Portfolio
184.108.40.206. SWOT Analysis
220.127.116.11. Financial Overview
18.104.22.168. Strategic Overview
16.3.11. Merck KGaA.
22.214.171.124. Company Overview (HQ, Business Segments, Employee Strength)
126.96.36.199. Product Portfolio
188.8.131.52. SWOT Analysis
184.108.40.206. Financial Overview
220.127.116.11. Strategic Overview
Fact.MR offers custom research services that help clients to get specific research solutions